Sobi is an international specialty healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients.

 Sobi has been involved
in the development and
manufacturing of
recombinant protein drugs
since the technology was first
developed more than
30 years ago.

 We want to make a difference
to people with rare diseases.

By working closely
with patients and their relatives
we learn about their daily
challenges and needs.


Sobi has a diversified and growth-oriented commercial product portfolio within three business lines.
To products


Sobi will broadcast daily a video blog from the ISTH conference in Toronto, Canada taking place 20-24 June 2015.
Go to

Annual General Meeting 2015

The Annual General Meeting in Swedish Orphan Biovitrum AB (publ), Reg. No. 556038-9321, was held on Tuesday, June 30, 2015 in Wallenbergsalen, the Royal Swedish Academy of Engineering Sciences (IVA), Grev Turegatan 16, Stockholm, Sweden
Read more

Presentation of Sobi's Interim Report April - June 2015

16 July, 2015 Sobi's Report for the first quarter was published - Revenues for the quarter totalled SEK 764 M (663), an increase of 15 per cent.

Share Price


Volume: 378,832
Ticker: SOBI
SSE Large